Skip to main content
Swedish Orphan Biovitrum logo

Swedish Orphan Biovitrum — Investor Relations & Filings

Ticker · SOBI ISIN · SE0000872095 LEI · 549300124Y3MQI87PT35 ST Manufacturing
Open in API
Filings indexed 892 across all filing types
Latest filing 2020-02-13 Interim / Quarterly Rep…
Country SE Sweden
Listing ST SOBI

About Swedish Orphan Biovitrum

https://www.sobi.com/en

Swedish Orphan Biovitrum (Sobi) is a specialized biopharmaceutical company dedicated to developing and delivering innovative treatments for rare and debilitating diseases. The company's primary focus is on the therapeutic areas of haematology and immunology, with a significant legacy and continued leadership in haemophilia care. Sobi addresses the high unmet medical needs of patients by advancing a pipeline of innovative medicines and working to expand patient access globally. The company's mission is to transform the lives of people affected by rare conditions through dedicated research, development, and global collaboration.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2019
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the fourth quarter and full year 2019, containing detailed financial tables (revenue, EBITA, EPS), management commentary ('Vd har ordet'), and operational reviews of business segments (Haematology, Immunology, Specialty Care). It provides actual financial data and analysis rather than just an announcement or certification. Therefore, it is classified as an Interim/Quarterly Report. Q4 2019
2020-02-13 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report Classification · 95% confidence The document provides a comprehensive review of the company's financial performance for the fourth quarter and full-year 2019, including detailed revenue breakdowns by business area (Haematology, Immunology, Specialty Care), CEO statements, and business reviews. It contains substantive financial data and analysis rather than being a brief announcement or a certification. Given it covers a period shorter than a full fiscal year (Q4) alongside full-year highlights, it is classified as an Interim/Quarterly Report. FY 2019
2020-02-13 English
Sobi’s full year 2019 revenue and EBITA higher than previous estimates
Earnings Release Classification · 100% confidence The document is explicitly titled "PRESS RELEASE" and announces that the company's revenue and EBITA for the full year 2019 were higher than previous estimates. It provides preliminary financial figures (revenue and EBITA ranges) and compares them to the previously issued outlook. Crucially, it states, "Sobi will announce its fourth quarter and full year 2019 report on Thursday 13 February 2020 at 8:00 am CET." This indicates the document is not the full Annual Report (10-K) or the comprehensive Interim Report (IR), but rather the initial, high-level announcement of the period's financial results, which aligns perfectly with the definition of an Earnings Release (ER). The document length is short (3409 chars) and it announces a future, more detailed report, confirming it is an initial release, not the final report itself. FY 2019
2020-01-16 English
Sobis intäkter och EBITA för helåret 2019 högre än tidigare estimat
Earnings Release Classification · 100% confidence The document is a press release dated January 16, 2020, titled "Sobis intäkter och EBITA för helåret 2019 högre än tidigare estimat" (Sobi's revenues and EBITA for the full year 2019 higher than previous estimates). It provides preliminary, unaudited financial highlights (revenues and EBITA) for the full year 2019, comparing them to previous guidance. Crucially, it states that the official full-year report (bokslutskommunikén) will be published on February 13, 2020. Since this document only announces preliminary results and highlights, and is not the comprehensive annual report (10-K) or the official quarterly report (IR), it best fits the definition of an Earnings Release (ER), which covers the initial announcement of periodical financial results (key highlights only). The document length is short (3292 chars), supporting the idea that it is a summary announcement rather than the full report. FY 2019
2020-01-16 Swedish
Sobi successfully completes acquisition of Dova Pharmaceuticals
M&A Activity Classification · 98% confidence The document is a "PRESS RELEASE" announcing the successful completion of an acquisition: "Sobi successfully completes acquisition of Dova Pharmaceuticals". This involves a tender offer, merger, and payment structure (cash plus Contingent Value Rights - CVRs). This type of corporate action, involving the purchase of another company, falls under Merger & Acquisition (M&A) activity. The corresponding code is TAR (M&A Activity). It is not an earnings release (ER), a capital change (CAP), or a general regulatory filing (RNS), as it specifically details a takeover transaction.
2019-11-12 English
Sobi har framgångsrikt slutfört förvärvet av Dova Pharmaceuticals
M&A Activity Classification · 98% confidence The document is titled "PRESSMEDDELANDE" (Press Release) and announces the successful completion of an acquisition: "Sobi har framgångsrikt slutfört förvärvet av Dova Pharmaceuticals". This describes a significant corporate transaction involving the purchase of one company by another. This falls under the category of Merger & Acquisition (M&A) activity. The corresponding code is TAR (M&A Activity). The document is a formal announcement, not the detailed legal filing (like 8-K or equivalent) or a general regulatory filing (RNS), but specifically details the closing of a takeover/merger proposal.
2019-11-12 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.